BioLife Solutions (BLFS) Set to Announce Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) will issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. BioLife Solutions has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative return on equity of 13.36% and a negative net margin of 46.37%. The firm had revenue of $32.73 million for the quarter, compared to the consensus estimate of $32.70 million. On average, analysts expect BioLife Solutions to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $18.60 on Wednesday. BioLife Solutions has a twelve month low of $8.92 and a twelve month high of $24.50. The stock’s 50 day moving average price is $17.41 and its 200-day moving average price is $15.80. The company has a market capitalization of $842.58 million, a PE ratio of -12.24 and a beta of 1.69. The company has a quick ratio of 1.83, a current ratio of 2.86 and a debt-to-equity ratio of 0.06.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group initiated coverage on BioLife Solutions in a research note on Thursday, April 4th. They issued a “buy” rating and a $22.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $23.40.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CEO Greef Roderick De sold 7,249 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $16.60, for a total transaction of $120,333.40. Following the sale, the chief executive officer now owns 461,854 shares of the company’s stock, valued at approximately $7,666,776.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Greef Roderick De sold 7,249 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $16.60, for a total value of $120,333.40. Following the transaction, the chief executive officer now owns 461,854 shares of the company’s stock, valued at $7,666,776.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $15.67, for a total transaction of $156,700.00. Following the completion of the transaction, the chief marketing officer now directly owns 129,644 shares in the company, valued at approximately $2,031,521.48. The disclosure for this sale can be found here. Insiders have sold 33,996 shares of company stock valued at $562,145 in the last 90 days. 2.70% of the stock is currently owned by company insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.